OncoMatch/Clinical Trials/NCT06405425
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Is NCT06405425 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including BL-B01D1 and PD-1 for urothelial carcinoma.
Treatment: BL-B01D1 · PD-1 — This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 combination therapy in patients with locally advanced or metastatic urothelial carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antibody-drug conjugate
Exception: ADC with TOPI inhibitors as toxin
Prior ADC recipients with TOPI inhibitors as toxin
Cannot have received: immunotherapy
Exception: prior immunotherapy with grade ≥3 irAE or grade ≥2 immune-related myocarditis
Prior immunotherapy with grade ≥3 irAE or grade ≥2 immune-related myocarditis
Cannot have received: radiation therapy
Exception: palliative radiotherapy within 2 weeks before the first dose
Palliative radiotherapy within 2 weeks before the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify